https://biotechmorning.com/news/gilead-13-billion-six-weeks-acquisition-spree Biotech Morning en 2026-04-12T14:12:57.510Z Gilead Just Spent $13 Billion in Six Weeks. What Do They Know? https://biotechmorning.com/news/big-pharma-china-biopharma-out-licensing-surge-2026 Biotech Morning en 2026-04-12T14:12:11.241Z Big Pharma Can't Stop Shopping in China https://biotechmorning.com/news/avalyn-pharma-ipo-lung-disease-bet Biotech Morning en 2026-04-12T14:11:25.851Z The Lung Disease Bet That's Banking on a $4 Billion Market Nobody's Cracked https://biotechmorning.com/news/oricell-110m-car-t-solid-tumors-ipo Biotech Morning en 2026-04-12T14:10:42.491Z The $110M Bet That CAR-T Can Finally Crack Solid Tumors https://biotechmorning.com/news/fda-rejects-replimune-rp1-melanoma-second-time Biotech Morning en 2026-04-12T14:10:03.125Z The FDA Just Rejected This Cancer Therapy. Again. https://biotechmorning.com/news/glp1-pill-foundayo-oral-obesity-drug-fda-approval Biotech Morning en 2026-04-12T14:09:22.453Z The GLP-1 Pill That Could Make Needles Obsolete https://biotechmorning.com/news/neurocrine-soleno-acquisition-prader-willi Biotech Morning en 2026-04-12T14:08:37.660Z Neurocrine Just Bet $2.9 Billion on a Disease Most People Have Never Heard Of https://biotechmorning.com/news/biotech-ipo-drought-over-q1-2026 Biotech Morning en 2026-04-12T14:07:58.532Z Biotech's IPO Drought Is Over. The Rain Is Coming in Buckets. https://biotechmorning.com/news/fda-rejects-replimune-melanoma-drug-twice Biotech Morning en 2026-04-11T14:12:46.330Z The FDA Just Rejected This Melanoma Drug Twice. Here's Why It Matters. https://biotechmorning.com/news/treefrog-ceo-joins-orano-med-alpha-therapy Biotech Morning en 2026-04-11T14:12:02.188Z Why a Stem Cell CEO Just Ditched His Own Field for Nuclear Medicine https://biotechmorning.com/news/medicine-cabinet-strait-of-hormuz-problem Biotech Morning en 2026-04-11T14:11:15.690Z Your Medicine Cabinet Has a Strait of Hormuz Problem https://biotechmorning.com/news/rna-biggest-problem-54m-bet Biotech Morning en 2026-04-11T14:10:32.882Z RNA's Biggest Problem Has a $54M Bet Behind It https://biotechmorning.com/news/biotech-velvet-rope-q1-2026-ipo-party Biotech Morning en 2026-04-11T14:09:50.822Z Biotech's Velvet Rope: Only the Biggest Names Got Into Q1's IPO Party https://biotechmorning.com/news/takeover-tuesday-lilly-biogen-biotech-ma-surge Biotech Morning en 2026-04-11T14:09:08.033Z Two Pharma Giants Went Shopping on the Same Day. Biotech Went Ballistic. https://biotechmorning.com/news/oral-glp1-pill-foundayo-obesity-approval Biotech Morning en 2026-04-11T14:08:26.351Z The Pill That Could Kill the Obesity Needle https://biotechmorning.com/news/fda-delay-killed-kezar-life-sciences Biotech Morning en 2026-04-11T14:07:37.590Z The FDA Canceled a Meeting. A Biotech Company Died.